Australia markets closed

Neurocrine Biosciences, Inc. (NBIX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
122.25+0.97 (+0.80%)
At close: 04:00PM EDT
122.00 -0.25 (-0.20%)
After hours: 06:27PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 12.25B
Enterprise value 11.46B
Trailing P/E 36.53
Forward P/E 16.23
PEG ratio (5-yr expected) 0.28
Price/sales (ttm)5.88
Price/book (mrq)4.88
Enterprise value/revenue 5.41
Enterprise value/EBITDA 18.65

Trading information

Stock price history

Beta (5Y monthly) 0.37
52-week change 37.85%
S&P500 52-week change 325.74%
52-week high 3157.98
52-week low 3103.63
50-day moving average 3141.51
200-day moving average 3136.17

Share statistics

Avg vol (3-month) 3916.67k
Avg vol (10-day) 31.23M
Shares outstanding 5100.98M
Implied shares outstanding 6100.98M
Float 899.77M
% held by insiders 10.99%
% held by institutions 196.16%
Shares short (30 Aug 2024) 42.14M
Short ratio (30 Aug 2024) 42.05
Short % of float (30 Aug 2024) 42.48%
Short % of shares outstanding (30 Aug 2024) 42.11%
Shares short (prior month 31 July 2024) 42.67M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 429 Dec 1995
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)30 June 2024

Profitability

Profit margin 16.00%
Operating margin (ttm)25.06%

Management effectiveness

Return on assets (ttm)11.51%
Return on equity (ttm)15.55%

Income statement

Revenue (ttm)2.12B
Revenue per share (ttm)21.38
Quarterly revenue growth (yoy)30.40%
Gross profit (ttm)N/A
EBITDA 569.4M
Net income avi to common (ttm)339.2M
Diluted EPS (ttm)3.32
Quarterly earnings growth (yoy)-31.90%

Balance sheet

Total cash (mrq)1.04B
Total cash per share (mrq)10.29
Total debt (mrq)291.6M
Total debt/equity (mrq)11.62%
Current ratio (mrq)4.19
Book value per share (mrq)24.87

Cash flow statement

Operating cash flow (ttm)530.4M
Levered free cash flow (ttm)496.06M